首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1736680

全球關節痛注射劑市場：市場規模（按類型、應用、通路和地區分類）、未來預測

Global Joint Pain Injections Market Size By Type (Steroid Joint Injections, Hyaluronic Acid Injections), By Application (Shoulder & Elbow, Knee & Ankle), By Distribution Channel (Hospital Pharmacies, Online Pharmacies), By Geographic Scope And Forecast

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

關節痛注射劑的市場規模與預測

2024 年關節痛注射市場規模價值為 54.6 億美元，預計到 2032 年將達到 99.6 億美元，2026 年至 2032 年的複合年成長率為 7.80%。

關節疼痛注射市場涵蓋全球用於緩解各種關節疾病相關疼痛和發炎的藥物交易。這些注射通常含有皮質類固醇、透明質酸、富血小板血漿 (PRP) 和其他生物製藥。關節疼痛注射為骨關節炎、類風濕性關節炎、肌腱炎、黏液囊炎和其他整形外科疾病等疾病提供了一種非侵入性或微創的手術干預替代方案。此細分市場面向廣泛的人群，包括老齡化相關關節退化的老年人和遭受運動傷害的運動員。

推動全球關節痛注射市場發展的因素

關節痛注射劑的市場驅動力可能受到多種因素的影響。這些因素包括：

人口老化：隨著全球人口老化，類風濕性關節炎和骨關節炎等關節相關疾病的發生率日益上升。預計這一人口趨勢將推動注射等關節疼痛管理療法的需求。

關節疾病增加：肥胖、久坐不動的生活方式、運動傷害和生活方式的改變導致關節疾病的發生率上升，因此需要注射等有效的緩解疼痛的技術。

偏好微創治療：患者通常更傾向於微創治療而非外科手術，因為微創治療恢復時間較短、併發症較少、住院時間較短。關節疼痛注射是治療疼痛和增強關節功能的手術替代方案。

技術發展：醫療技術的進步促成了比傳統治療方法更安全、更有效的新型注射療法的開發，例如關節內粘稠補充療法和富血小板血漿 (PRP) 注射。

提高意識和接受度：由於人們廣泛了解早期療育和有效疼痛管理技術的益處，患者和醫療保健專業人員擴大接受注射劑治療關節疼痛。

發展醫療保健基礎設施：發展醫療保健基礎設施，特別是在新興經濟體，可以讓人們更多地獲得關節痛注射劑等專科治療，從而增加市場潛力。

策略夥伴關係和協作：製藥公司、醫療設備製造商和醫療保健提供者之間的聯盟和協作正在促進新型注射關節痛藥物和技術的開發、傳播和採用。

監管支持：關節痛注射劑市場研發支出受到監管機構的優惠政策和舉措的刺激，這些政策和舉措支持採用創新治療方法並加快新治療方法的核准流程。

限制全球關節痛注射劑市場的因素

關節痛注射劑市場面臨許多限制和挑戰，其中包括：

療效和長期效果有限：雖然關節疼痛注射可以緩解症狀，但可能無法有效阻止病情長期發展，導致患者和醫療保健相關人員不滿，並阻礙市場擴張。

昂貴的治療：一些關節疼痛注射劑，尤其是較新的、更先進的注射劑，價格昂貴。經濟方面的擔憂可能會阻礙患者接受這些治療，尤其是在醫療保健服務匱乏或自付費用較高的地區。

副作用與安全問題：雖然關節疼痛注射被認為是一種微創治療方法，但它們也存在組織損傷、過敏反應、感染疾病。安全問題可能會影響醫生和病人的意見，阻礙市場接受。

監管障礙：嚴格的監管和冗長的核准流程可能會延遲新型關節痛注射劑的上市，而且遵守不同地區不同的監管規範可能會很困難。

來自替代療法的競爭：口服藥物、物理治療、手術等是關節疼痛注射必須面對的替代療法。注射劑的市場佔有率可能會受到替代療法可用性的限制。

支付規則有限：支付規則不完善可能會阻礙患者獲得關節疼痛注射劑，尤其是昂貴藥物或新藥。報銷問題可能會影響治療費用的可負擔性以及醫生注射的意願，從而可能影響市場擴張。

市場分散化與整合：關節痛注射劑市場參與者眾多，產品眾多，導致市場分散化。激烈的競爭和主要參與者的整合嘗試可能導致價格壓力和利潤率下降。

病患偏好與依從性問題：注射關節痛藥物的使用可能受到病患偏好、治療預期和信念的影響。患者對治療方法的依從性和堅持性可能受到針頭恐懼症、對侵擾感的感知以及不願重複注射等因素的影響。

The Joint Pain Injections Market encompasses the global trade in pharmaceutical products designed to alleviate pain and inflammation associated with various joint disorders. These injections typically include corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and other biologic agents. Joint pain injections offer a non-invasive or minimally invasive alternative to surgical interventions for conditions such as osteoarthritis, rheumatoid arthritis, tendinitis, bursitis, and other orthopedic ailments. This market segment caters to a wide range of demographics, including the elderly population experiencing age-related joint degeneration and athletes suffering from sports-related injuries.

Global Joint Pain Injections Market Drivers

The market drivers for the Joint Pain Injections Market can be influenced by various factors. These may include:

Ageing Population: As the world's population ages, joint-related conditions including rheumatoid arthritis and osteoarthritis are becoming more common. It is anticipated that this demographic trend would fuel demand for joint pain management therapies, such as injections.

Growing Incidence of Joint illnesses: Obesity, sedentary lifestyles, sports injuries, and lifestyle modifications all contribute to the rising prevalence of joint illnesses, which calls for efficient pain relief techniques like injections.

Preference for Minimally Invasive Treatments: Because minimally invasive treatments have shorter recovery times, fewer problems, and shorter hospital stays, patients frequently favour them over surgical methods. An alternative to surgery for treating pain and enhancing joint function is joint pain injections.

Technological Developments: As a result of ongoing improvements in medical technology, novel injection therapies with better safety and efficacy profiles than conventional treatments have been developed. Examples of these therapies include viscosupplementation and platelet-rich plasma (PRP) injections.

Growing Awareness and Acceptance: Patients and medical professionals alike are becoming more receptive to joint pain injections as a result of growing knowledge about the advantages of early intervention and efficient pain management techniques.

Development of Healthcare Infrastructure: Access to specialised therapies, such as joint pain injections, has increased due to improvements in healthcare infrastructure, particularly in emerging nations. This has expanded the market potential.

Strategic Partnerships and Collaborations: The development, dissemination, and uptake of novel joint pain injection products and technologies are facilitated by partnerships and collaborations among pharmaceutical companies, makers of medical devices, and healthcare providers.

Regulatory Support: Research and development expenditures in the joint pain injections market are stimulated by favourable regulatory policies and initiatives that support the adoption of innovative medical treatments and by accelerated approval processes for novel therapies.

Global Joint Pain Injections Market Restraints

Several factors can act as restraints or challenges for the Joint Pain Injections Market. These may include:

Limited Effectiveness and Long-Term Results: Although joint pain injections relieve symptoms, it's possible that they won't be as effective in stopping the progression of the condition over the long run. Patients' and healthcare professionals' unhappiness may result from this, which could hinder market expansion.

Expensive Treatment: Several joint pain injections, particularly the more recent and sophisticated ones, can be costly. Patients may be discouraged from pursuing these treatments due to financial concerns, especially in areas with little access to healthcare or high out-of-pocket costs.

Adverse Effects and Safety Concerns: Although joint pain injections are considered minimally invasive procedures, there are still potential hazards linked with them, such as tissue damage, allergic reactions, and infection. Concerns about safety could sway the opinions of doctors and patients, which would hinder market acceptance.

Regulatory Obstacles: Tight regulations and lengthy approval procedures may cause a lag in the release of novel joint pain injection solutions. Manufacturers may also have difficulties in adhering to differing regulatory norms in various geographical areas.

Competition from Alternative Therapies: Oral drugs, physical therapy, and surgical procedures are some of the alternative treatments that joint pain injections must contend with. The market share of injections may be restricted by the availability of alternative treatment options, particularly if these choices are thought to be equally or more effective.

Limited payment rules: Patients' access to joint pain injections may be hampered by inadequate payment rules, especially for expensive or novel medicines. Issues with reimbursement may affect treatment affordability and physicians' willingness to give injections, which may have an effect on market expansion.

Market Fragmentation and Consolidation: There are many manufacturers and products in the joint pain injections market, which causes market fragmentation. Price pressure and narrowed profit margins may be the outcome of fierce rivalry and major firms' attempts to consolidate.

Patient Preference and Compliance Issues: The use of joint pain injections may be influenced by a patient's preferences, treatment expectations, and beliefs. Patient compliance and adherence to treatment regimens may be impacted by variables such needle phobia, the perception of being intrusive, and reluctance to get repeated injections.

Global Joint Pain Injections Market Segmentation Analysis

The Global Joint Pain Injections Market is segmented on the basis of Type, Application, Distribution Channel, And Geography.

Joint Pain Injections Market, By Type

Steroid Joint Injections
Hyaluronic Acid Injections
Platelet-Rich Plasma (PRP) Injections
Others

Based on Type, The market is bifurcated into Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-Rich Plasma (PRP) Injections, and Others.

Joint Pain Injections Market, By Application

Shoulder & Elbow
Knee & Ankle
Spinal Joints
Others

Based on Application, The market is bifurcated into Shoulder & Elbow, Knee & Ankle, Spinal Joints, and Others.

Joint Pain Injections Market, By Distribution Channel

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Based on Distribution Channel, The market is bifurcated into Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others.

Joint Pain Injections Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Geography, The Global Joint Pain Injections Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America may dominate the market due to the high prevalence of musculoskeletal disorders that causes joint pains. Increasing awareness of Non-invasive orthopedic treatments, continuous innovation in implant technologies, and advanced healthcare facilities.

Key Players

The "Global Joint Pain Injections Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Anika Therapeutics, Inc, Pfizer Inc, Zimmer Biomet Holdings Inc., Flexion Therapeutics Inc, SEIKAGAKU CORPORATION, Allergan Plc, Chugai Pharmaceutical Co., Ltd, Bioventus LLC, Ferring B.V, and Sanofi S.A.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

December 2019: Flexion Therapeutics Inc, announced the U.S. FDA approval of the Supplemental New Drug Application to update the product label of ZILRETTA and give more clear information about the product.

1 INTRODUCTION OF GLOBAL JOINT PAIN INJECTIONS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL JOINT PAIN INJECTIONS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL JOINT PAIN INJECTIONS MARKET, BY TYPE

5.1 Overview
5.2 Steroid Joint Injections
5.3 Hyaluronic Acid Injections
5.4 Platelet-Rich Plasma (PRP) Injections
5.5 Others

6 GLOBAL JOINT PAIN INJECTIONS MARKET, BY APPLICATION

6.1 Overview
6.2 Shoulder & Elbow
6.3 Knee & Ankle
6.4 Spinal Joints
6.5 Others

7 GLOBAL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

7.1 Overview
7.2 Hospital Pharmacies
7.3 Online Pharmacies
7.4 Retail Pharmacies
7.5 Others

8 GLOBAL JOINT PAIN INJECTIONS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL JOINT PAIN INJECTIONS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Anika Therapeutics Inc
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Pfizer Inc
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Zimmer Biomet Holdings Inc
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Flexion Therapeutics, Inc
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 SEIKAGAKU CORPORATION
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Allergan Plc
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Chugai Pharmaceutical Co. Ltd.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Bioventus LLC
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Ferring B.V
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Sanofi S.A.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments